{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Analyze the plasma inhibitory activity (PIA) for FLT3 phosphorylation in peripheral blood samples obtained at the time of PK studies in patients with FLT3-ITD mutation AML (Part C).","groups":[{"description":"Patients receive oral sorafenib 150 mg/m\\^2 every 12 hours.","id":"OG000","title":"Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 week prior to enrollment and then every 28 days","title":"Plasma Inhibitory Activity (PIA)","type":"SECONDARY","unitOfMeasure":"Participants"}